Oncology

Oncology

Access New Insights in Precision Oncology

Powered by Phase Genomics’ ultra-long-range genome sequencing technology, the OncoTerra™ Platform leverages the unique strengths of proximity ligation to characterize the breadth of chromosome abnormalities in a single assay.

 

High-resolution view of inversions, translocations, and copy number variants form a single NGS-based assay

Standard-of-care cytogenetics requires a battery of tests which may include karyotyping, FISH, and chromosomal microarray (CMA) to capture clinically relevant variants and guide treatment. The OncoTerra™ Platform captures these results in a single assay, and provides a high-resolution view of translocation and inversion breakpoints not attainable with other methods. OncoTerra is compatible with FFPE samples, enabling cytogenomic analysis of archival samples for retrospective studies. From one sample to a plate of 96, OncoTerra meets modern cytogenetic needs without specialized instrumentation.
Circos plot provides a genome-wide view Coverage and minor allele frequency support deletion calls
Detection of t(6;11) creating a KMT2A::AFDN fusion Identification of inv(16) creating a CBFB::MYH11 fusion

 

Comprehensive cytogenomics of fresh, frozen, and FFPE tissue in a single, genome-wide NGS assay

Unlock the wealth of potential diagnostic and prognostic information contained within non-viable, FFPE, frozen, and fresh samples.
Ultra-long-range sequencing does not require actively dividing cells or high molecular weight DNA extraction.
Reduce turnaround time and cost by characterizing the breadth of chromosome abnormalities in a single, scalable NGS-based assay.
Simultaneously detect all major types of genomic rearrangements that cause and characterize disease, on a genome-wide scale.

OncoTerra Case Study: AML »

Download to learn more

OncoTerra Applications Summary »

Download to learn more

Automated analytics yield actionable results

The OncoTerra Platform provides a sample-to-report NGS-based cytogenomics assay that starts with a solid tumor (e.g., FFPE) or hematological sample, and ends with a comprehensive and actionable report in standard and sequence-based nomenclature.Fully automated, cloud-based analysis of paired-end Illumina® sequencing data is performed with Phase Genomics’ proprietary computational tools.The entire process can be completed in less than a week, and is scalable to large numbers of samples.

The OncoTerra Platform is currently offered by Phase Genomics as a comprehensive sample-to-report service. Contact us to inquire about RUO kits compatible with existing low- and high-throughput sample processing pipelines.